Cho J, et al. - In people with pancreatic cancer–related diabetes (PCRD) and postpancreatitis diabetes mellitus (PPDM), researchers determined the risk of mortality correlated with the use of antidiabetic medications. There were 1,862 individuals with PCRD or PPDM found via nationwide pharmaceutical dispensing data (2006–2015) linked to hospital discharge data. Ever-users of metformin and ever-users of insulin had significantly lower risks of mortality vs never-users of antidiabetic medications in people with PCRD. In individuals with PPDM, but not PCRD, metformin promotes survival benefit. In the connection between insulin use and mortality in PCRD, reverse causality can play a part. Individuals with PPDM who were ever-users of metformin had a significantly reduced risk of mortality; ever-users of insulin did not have a significantly changed risk of mortality vs never-users of antidiabetic medications.